Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

GSK's Jemperli (dostarlimab-gxly) received FDA approval as the first immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer. Approval based on AZUR-1 trial data showing 68% of patients had no detectable cancer after one year. GSK aims to offer an alternative to chemotherapy, radiation, and surgery for eligible patients. The company plans to present full data at the ESMO Congress in October 2026.

Original reporting
Published Oct 19, 2026, 4:36 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 5:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer — source image
Decision brief

The 30-second read

$GSKBullishHigh
01

Why it matters

The approval expands GSK's immuno‑oncology portfolio and may drive short‑term stock gains.

02

Market read

Regulatory approval is a primary catalyst for GSK's stock and the broader oncology sector.

03

What to watch

Reimbursement negotiations and competition from other PD‑1 inhibitors could limit upside.

Relevance 7/10Novelty 9/10Timing: today

Background

GSK announced the FDA's accelerated approval of Jemperli for a specific rectal cancer indication, highlighting trial data and regulatory designations.

Company-level read

Ticker impact

$GSKBullishHigh confidence
Context

FDA granted accelerated approval for Jemperli (dostarlimab-gxly) as the first immunotherapy for MSI-H/dMMR locally advanced rectal cancer.

Expected impact

likely upward pressure as investors price in new oncology indication.

Evidence & confidence

Regulatory approval is a material catalyst; the drug targets a niche but high‑need patient group and adds to GSK's pipeline.

Market effects

Strengthens the biotech/oncology segment and may lift peer immunotherapy stocks.

Positive for European pharma markets where GSK is a major component.

Adds to the pipeline of FDA‑approved cancer therapies, relevant to global oncology investors.

Counterpoint

If the drug fails to achieve commercial uptake, the approval may not translate into meaningful revenue.

Key entities

  • GSK plc

    Global pharmaceutical company receiving FDA approval.

  • FDA

    U.S. agency granting accelerated approval.

Related articles

$GSKMed

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

GSK's Nelkarmi (neladalkib) received FDA accelerated approval for ALK-positive NSCLC patients after prior ALK therapy. Approval based on ALKOVE-1 trial showing 49% tumor shrinkage in Alecensa-only group. GSK acquired Nelkarmi via Nuvalent acquisition. Continued approval contingent on confirmatory trial. ALKAZAR phase 3 trial ongoing for first-line treatment.

$GSKMedAI 8/10

GSK’s $10.6bn Nuvalent bet pays off with second lung cancer drug approval

GSK's Nelkarmi (neladalkib) received FDA approval for treating ALK-positive non-small cell lung cancer, the second drug from its $10.6bn Nuvalent acquisition. The approval was based on trial results showing a 49% response rate. GSK expects significant sales, with forecasts predicting $1.2bn by 2032. Roche's Alecensa is a key competitor. Approval hinges on ongoing Phase III trial results.

$GSKMed

GSK Wins Second Lung Cancer Approval of 2026 as FDA Clears Nelkarmi — BigGo Finance

GSK (GSK) received FDA approval for Nelkarmi, a lung cancer drug, based on Phase 1/2 trial data. The drug targets ALK gene mutations and showed activity against brain metastases. GSK acquired Nelkarmi through its $10.6B Nuvalent deal. Analysts project $1B in 2032 sales, with peak sales estimates of $5B-$7B for GSK's lead Nuvalent drugs. The approval is seen as a validation of GSK's oncology portfolio strategy.

$SMMTMedAI 8/10

FDA publishes rejection letter for Summit drug; Nuvalent buyout pays more dividends for GSK

FDA rejected Summit Therapeutics' ivonescimab for lung cancer, citing insufficient benefits. Sellas Life Sciences' cancer vaccine showed 41% reduced death risk in a Phase 3 trial. GSK's Nelkarmi, acquired via Nuvalent buyout, gained FDA approval for lung cancer. AstraZeneca's gefurulimab was approved for myasthenia gravis. Eli Lilly partnered with Stipple Bio for cancer drugs, potentially worth $5.9B. Biogen invested $32M in Trimtech for neurodegenerative disease treatments.

$GSKMed

GSK gets second cancer drug approval from Nuvalent buy

GSK's Nelkarmi (neladalkib) received FDA approval for ALK-positive NSCLC after prior ALK inhibitor treatments. The approval follows GSK's $10.6B acquisition of Nuvalent. Analysts project Nelkarmi, Jideytro, and NVL-330 could generate $5B-$7B in annual sales. Nelkarmi showed a 49% objective response rate in trials. GSK aims to boost revenues to £40B by 2031.